Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Bacterial Infections and Mycoses

  Free Subscription


Articles published in Am J Respir Crit Care Med

Retrieve available abstracts of 50 articles:
HTML format



Single Articles


    September 2025
  1. SOBOL R, Omar SV, Brown T, Joseph L, et al
    Transmission of Bedaquiline-resistant Mycobacterium tuberculosis in KwaZulu-Natal, South Africa.
    Am J Respir Crit Care Med. 2025 Sep 30. doi: 10.1164/rccm.202506-1489.
    PubMed     Abstract available


  2. ORTEGA VE, Pienaar E, Escalante P
    Genetic Susceptibility to Non-Tuberculous Mycobacterial Pulmonary Disease, Is the Chicken or the Egg?
    Am J Respir Crit Care Med. 2025 Sep 25. doi: 10.1164/rccm.202508-1970.
    PubMed    


  3. LOADER MI, Vasquez Alves SE, Vasquez Alves NL, Coronel J, et al
    IgE, Matrix Metalloproteinases, and Tuberculosis: Immunologic Consequences of Helminth Co-Infection.
    Am J Respir Crit Care Med. 2025 Sep 23. doi: 10.1164/rccm.202507-1710.
    PubMed    


  4. MARTINEZ L, Campbell JI, Linde L, Boulahbal F, et al
    The Effectiveness of Isoniazid Preventive Treatment among Contacts of Multidrug-Resistant Tuberculosis: A Systematic Review and Individual-Participant Meta-Analysis.
    Am J Respir Crit Care Med. 2025 Sep 23. doi: 10.1164/rccm.202411-2340.
    PubMed     Abstract available


  5. MENDELSOHN SC, Jackson GT, Wessels E, Beyers E, et al
    Oral Rinse versus Facemask Capture for Non-Sputum Diagnosis of Pulmonary Tuberculosis.
    Am J Respir Crit Care Med. 2025 Sep 12. doi: 10.1164/rccm.202506-1477.
    PubMed    


  6. GORDHAN BG, Sewcharran A, Waja Z, Martinson N, et al
    Oral Rinse as an Alternative Diagnostic Specimen for Detection of Tuberculosis.
    Am J Respir Crit Care Med. 2025 Sep 12. doi: 10.1164/rccm.202503-0723.
    PubMed    


    July 2025
  7. TRAUTH J, Laspoulas A, Dakischew O, Gentil K, et al
    Bedaquiline-Pretomanid-Linezolid as a Bridging Therapy for Adverse Events in Drug-Sensitive Tuberculosis.
    Am J Respir Crit Care Med. 2025 Jul 18. doi: 10.1164/rccm.202501-0150.
    PubMed    


  8. HULL RC, Stobo J, Abo-Leyah H, Richardson H, et al
    Endotypes of Pseudomonas aeruginosa Infection in Bronchiectasis Are Associated with Inhaled Antibiotic Response: Results from Two Randomised, Double-Blind, Placebo-controlled, Phase III Trials (ORBIT 3 and ORBIT 4).
    Am J Respir Crit Care Med. 2025 Jul 15. doi: 10.1164/rccm.202501-0159.
    PubMed     Abstract available


  9. MASIAS-LEON Y, Ruiz-Gonzalez CE, Nino-Meza OJ, Singh M, et al
    Dynamic (11)C-Para-Aminobenzoic Acid Positron Emission Tomography/Computed Tomography for Visualizing Pulmonary Mycobacteroides abscessus Infections.
    Am J Respir Crit Care Med. 2025;211:1253-1263.
    PubMed     Abstract available


  10. PHILLIPS PPJ, Peloquin CA, Sterling TR, Kaur P, et al
    Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial.
    Am J Respir Crit Care Med. 2025;211:1277-1287.
    PubMed     Abstract available


    June 2025
  11. SAUKKONEN J, Munsiff S, Winston C, Duarte R, et al
    Reply to Wilson et al.: The 4-Month HPMZ Treatment Regimen for Drug-Susceptible Pulmonary Tuberculosis - A Word of Caution.
    Am J Respir Crit Care Med. 2025.
    PubMed    


  12. WILSON JW, Temesgen Z MD, Gaensbauer JG
    The 4-Month HPMZ Treatment Regimen for Drug-Susceptible Pulmonary Tuberculosis - A Word of Caution.
    Am J Respir Crit Care Med. 2025.
    PubMed    


  13. XIA Y, Jiang W, Zhu X, Pan B, et al
    Global, Regional, and National Burden of Pulmonary Fungal Infections 1990-2021.
    Am J Respir Crit Care Med. 2025;211:1007-1017.
    PubMed     Abstract available


  14. MENZIES NA, Marks SM, Hsieh YL, Swartwood NA, et al
    Contribution of Posttuberculosis Sequelae to Life-Years Lost from Tuberculosis Disease in the United States, 2015-2019.
    Am J Respir Crit Care Med. 2025;211:1059-1068.
    PubMed     Abstract available


    May 2025
  15. THOMSON RM, Wheeler N, Stockwell RE, Bryant J, et al
    Infection by Clonally Related Mycobacterium abscessus Isolates: The Role of Drinking Water.
    Am J Respir Crit Care Med. 2025;211:842-853.
    PubMed     Abstract available


    March 2025
  16. JANSSEN S, Upton C, de Jager VR, van Niekerk C, et al
    Telacebec, A Potent Agent in the Fight Against Tuberculosis: Findings from A Randomized, Phase 2 Clinical Trial and Beyond.
    Am J Respir Crit Care Med. 2025 Mar 21. doi: 10.1164/rccm.202408-1632.
    PubMed     Abstract available


    February 2025
  17. RUMPF CH, Janssen T, Hait RJ, Romme K, et al
    Mucoid Staphylococcus aureus - Prevalence and Association with Lung Function in People with Cystic Fibrosis.
    Am J Respir Crit Care Med. 2025 Feb 7. doi: 10.1164/rccm.202407-1474.
    PubMed     Abstract available


    January 2025
  18. SAUKKONEN JJ, Duarte R, Munsiff SS, Winston CA, et al
    Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
    Am J Respir Crit Care Med. 2025;211:15-33.
    PubMed     Abstract available


    December 2024
  19. DERENDINGER B, Mochizuki TK, Marcelo D, Shankar D, et al
    C-reactive Protein-based Screening of People with Tuberculosis Symptoms: A Diagnostic Accuracy Study.
    Am J Respir Crit Care Med. 2024 Dec 6. doi: 10.1164/rccm.202405-1000.
    PubMed     Abstract available


    November 2024
  20. EPELBAUM O, Marinelli T, Haydour QS, Pennington KM, et al
    Treatment of Invasive Pulmonary Aspergillosis and Preventive and Empirical Therapy for Invasive Candidiasis in Adult Pulmonary and Critical Care Patients. An Of fi cial American Thoracic Society Clinical Practice Guideline.
    Am J Respir Crit Care Med. 2024 Nov 18. doi: 10.1164/rccm.202410-2045.
    PubMed     Abstract available



  21. Erratum: Who Transmits Tuberculosis to Whom: A Cross-Sectional Analysis of a Cohort Study in Lima, Peru.
    Am J Respir Crit Care Med. 2024;210:1280.
    PubMed    


    September 2024
  22. LORE NI, Gramegna A, de Pretis S, Di Marco F, et al
    Single-Cell RNA Sequencing Shows that Circulating Monocytes Enriched in IFN Signaling Are Associated with Nontuberculous Mycobacteria Pulmonary Disease in Cystic Fibrosis.
    Am J Respir Crit Care Med. 2024;210:834-837.
    PubMed    


    August 2024
  23. MORGAN SJ, Nichols DP, Ni W, Hong G, et al
    Elexacaftor/Tezacaftor/Ivacaftor Markedly Reduces Aspergillus fumigatus in Cystic Fibrosis.
    Am J Respir Crit Care Med. 2024 Aug 27. doi: 10.1164/rccm.202406-1128.
    PubMed    


  24. ZAVALA S, Stout JE
    A Balancing Act: Finding the Right Dose of Pyrazinamide to Treat Tuberculosis.
    Am J Respir Crit Care Med. 2024 Aug 22. doi: 10.1164/rccm.202406-1262.
    PubMed    


  25. AULD SC, Barczak AK, Bishai W, Coussens AK, et al
    Pathogenesis of Post-Tuberculosis Lung Disease: Defining Knowledge Gaps and Research Priorities at the 2(nd) International Post-Tuberculosis Symposium.
    Am J Respir Crit Care Med. 2024 Aug 14. doi: 10.1164/rccm.202402-0374.
    PubMed     Abstract available


  26. ROCHE SM, Ottewill C, Mulpeter R, Brown K, et al
    Delayed Tuberculosis Paradoxical Reaction Associated with TNF Inhibitors.
    Am J Respir Crit Care Med. 2024 Aug 12. doi: 10.1164/rccm.202402-0464.
    PubMed    


    July 2024
  27. COHEN T, Colijn C, Warren JL
    Approaches for M. tuberculosis Transmission Inference Based on Genomic Data.
    Am J Respir Crit Care Med. 2024 Jul 17. doi: 10.1164/rccm.202404-0835.
    PubMed    


  28. LEE WC
    Pairs or Paradoxes: Questioning Assumptions in Tuberculosis Transmission Research.
    Am J Respir Crit Care Med. 2024 Jul 17. doi: 10.1164/rccm.202405-0958.
    PubMed    


  29. XU AY, Velasquez GE, Zhang N, Chang VK, et al
    Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized, Controlled Clinical Trial.
    Am J Respir Crit Care Med. 2024 Jul 16. doi: 10.1164/rccm.202401-0165.
    PubMed     Abstract available


  30. MOSSOP M, Ish-Horowicz J, Hughes D, Dobra R, et al
    Chronicity Counts: The Impact of Pseudomonas aeruginosa, Staphylococcus aureus, and Coinfection in Cystic Fibrosis.
    Am J Respir Crit Care Med. 2024;210:240-242.
    PubMed    


    June 2024
  31. CRABBE A
    Intracellular Pseudomonas aeruginosa: An Overlooked Reservoir in the Lungs of People with Cystic Fibrosis?
    Am J Respir Crit Care Med. 2024;209:1421-1423.
    PubMed    


  32. MALET K, Faure E, Adam D, Donner J, et al
    Intracellular Pseudomonas aeruginosa within the Airway Epithelium of Cystic Fibrosis Lung Tissues.
    Am J Respir Crit Care Med. 2024;209:1453-1462.
    PubMed     Abstract available


  33. FEYS S, Cardinali-Benigni M, Lauwers HM, Jacobs C, et al
    Profiling Bacteria in the Lungs of Patients with Severe Influenza Versus COVID-19 with or without Aspergillosis.
    Am J Respir Crit Care Med. 2024 Jun 12. doi: 10.1164/rccm.202401-0145.
    PubMed     Abstract available


    May 2024
  34. ZHANG M, Yang C, Guo Y
    Aspergilloma in Cavity.
    Am J Respir Crit Care Med. 2024 May 31. doi: 10.1164/rccm.202312-2348.
    PubMed    


  35. CRABBE A
    Moving Beyond Antibiotics: Exploring the Potential of an Anti-Virulence Monoclonal Antibody Against Pseudomonas aeruginosa in Bronchiectasis.
    Am J Respir Crit Care Med. 2024 May 23. doi: 10.1164/rccm.202405-0974.
    PubMed    


  36. LONG MB, Gilmour A, Kehl M, Tabor D, et al
    A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Neutrophil-Mediated Killing of Pseudomonas aeruginosa in Patients with Bronchiectasis.
    Am J Respir Crit Care Med. 2024 May 16. doi: 10.1164/rccm.202308-1403.
    PubMed     Abstract available


  37. MARTINEZ-GARCIA MA
    The Heterogeneous World of Non-Tuberculous Mycobacteria in Bronchiectasis.
    Am J Respir Crit Care Med. 2024 May 15. doi: 10.1164/rccm.202405-0936.
    PubMed    


  38. GILMORE A, Ortiz J
    Pneumococcal Vaccines.
    Am J Respir Crit Care Med. 2024;209:P5-P7.
    PubMed    


  39. LI L, Henkle E, Youngquist BM, Seo S, et al
    Serum Cell-Free DNA-based Detection of Mycobacterium avium Complex Infection.
    Am J Respir Crit Care Med. 2024;209:1246-1254.
    PubMed     Abstract available


  40. MCSHANE PJ, Brunton AE, Choate R, Marmor M, et al
    The Impact of Tobacco Smoking in Bronchiectasis: Data from the United States Bronchiectasis and NTM Research Registry.
    Am J Respir Crit Care Med. 2024 May 7. doi: 10.1164/rccm.202402-0466.
    PubMed    


  41. DAVIES GR
    Reconsidering the Role of Isoniazid in Drug-resistant Tuberculosis.
    Am J Respir Crit Care Med. 2024 May 1. doi: 10.1164/rccm.202403-0628.
    PubMed    


    April 2024
  42. MATHEMA B, Burzynski J
    One Half of the Pair: Prioritizing Tuberculosis Transmitters for Early Detection.
    Am J Respir Crit Care Med. 2024 Apr 30. doi: 10.1164/rccm.202404-0699.
    PubMed    


  43. AKSAMIT TR, Locantore N, Addrizzo-Harris D, Ali J, et al
    Five-Year Outcomes Among U.S. Bronchiectasis and Nontuberculous Mycobacterial Registry Patients.
    Am J Respir Crit Care Med. 2024 Apr 26. doi: 10.1164/rccm.202307-1165.
    PubMed     Abstract available


  44. DRAIN PK
    Another Step Closer to Genomic-informed Therapeutic Dosing for Tuberculosis Drugs.
    Am J Respir Crit Care Med. 2024 Apr 22. doi: 10.1164/rccm.202403-0566.
    PubMed    


  45. GAUSI K, Ignatius EH, De Jager V, Upton C, et al
    High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial.
    Am J Respir Crit Care Med. 2024 Apr 2. doi: 10.1164/rccm.202311-2004.
    PubMed     Abstract available


  46. ZHANG M, Luo Q, Li X, Mu X, et al
    Pulmonary Artery Pseudoaneurysm Caused by Pulmonary Mucormycosis.
    Am J Respir Crit Care Med. 2024;209:879-880.
    PubMed    


    March 2024
  47. AHMAD S, Wrennall JA, Goriounova AS, Sekhri M, et al
    Specific Inhibition of Orai1-mediated Calcium Signalling Resolves Inflammation and Clears Bacteria in an Acute Respiratory Distress Syndrome Model.
    Am J Respir Crit Care Med. 2024;209:703-715.
    PubMed     Abstract available


  48. VERMA R, Silva KED, Rockwood N, Wasmann RE, et al
    A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.
    Am J Respir Crit Care Med. 2024 Mar 5. doi: 10.1164/rccm.202309-1583.
    PubMed     Abstract available


    February 2024
  49. TREVISI L, Brooks MB, Becerra MC, Calderon RI, et al
    Who Transmits Tuberculosis to Whom: A Cross-Sectional Analysis of a Cohort Study in Lima, Peru.
    Am J Respir Crit Care Med. 2024 Feb 28. doi: 10.1164/rccm.202307-1217.
    PubMed     Abstract available


    January 2024
  50. MAC AOGAIN M, Xaverius Ivan F, Jaggi TK, Richardson H, et al
    Airway 'Resistotypes' and Clinical Outcomes in Bronchiectasis.
    Am J Respir Crit Care Med. 2024 Jan 25. doi: 10.1164/rccm.202306-1059.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bacterial Infections and Mycoses is free of charge.